Gonadotrophin-releasing hormone antagonists for assisted conception: a Cochrane Review
Tóm tắt
Từ khóa
Tài liệu tham khảo
Albano, 2000, Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin, Human Reproduction, 15, 526, 10.1093/humrep/15.3.526
Albano, 1996, Hormonal profile during the follicular phase in cycles stimulated with a combination of human menopausal gonadotrophin and gonadotrophin-releasing hormone antagonist (cetrorelix), Human Reproduction, 11, 2114, 10.1093/oxfordjournals.humrep.a019058
Badrawi, 2005, Agonist versus antagonist in ICSI cycles: a randomized trial and cost effectiveness analysis, Middle East Fertility Society Journal, 10, 49
Bahçeci, 2005, Use of a GnRH antagonist in controlled ovarian hyperstimulation for assisted conception in women with polycystic ovary disease: a randomized, prospective, pilot study, Journal of Reproductive Medicine, 50, 84
Barmat, 2005, A randomized prospective trial comparing gonadotropin-releasing hormone (GnRH) antagonist/recombinant follicle-stimulating hormone (rFSH) versus GnRH-agonist/rFSH in women pretreated with oral contraceptives before in vitro fertilization, Fertility and Sterility, 83, 321, 10.1016/j.fertnstert.2004.06.076
Brelik P, Kurzawa R, Baczkowski T et al. 2004 Assessment of the predictive value of LH levels in IVF cycles stimulated with GnRH antagonists and agonists. In: Abstracts of the 20th Annual Meeting of the ESHRE, Berlin, Germany, June 2004. Human Reproduction 19 (suppl. 1), O–176.
Causio, 2004, GnRH agonist versus GnRH antagonist in an IVF program: luteal phase hormonal characteristics. In: Abstracts of the 20th Annual Meeting of the ESHRE, Berlin, Germany, June 2004, Human Reproduction, 19, P
Check, 2004, Effect of antagonists vs agonists on in vitro fertilization outcome, Clinical and Experimental Obstetrics and Gynecology, 31, 257
Cheung, 2005, GnRH antagonist versus long GnRH agonist protocol in poor responders undergoing IVF: a randomized controlled trial, Human Reproduction, 20, 616, 10.1093/humrep/deh668
Daya S 1998 Gonadotropin releasing hormone agonist protocols for pituitary desensitization in in vitro fertilization and gamete intrafallopian transfer cycles. In: The Cochrane Library, [database on CD Rom]. The Cochrane Collaboration, 4. Wiley, Chichester.
El Sahwi S 2005 GnRH agonists versus GnRH antagonists in controlled ovarian stimulation in ICSI trials. In: Book of Abstracts, 8th International Symposium on GnRH Analogues in Cancer and Human Reproduction, Salzburg, Austria, A65.
European and Middle East Orgalutran Study Group, 2001, Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation, Human Reproduction, 16, 644, 10.1093/humrep/16.4.644
European Orgalutran Study Group, 2000, Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial, Human Reproduction, 15, 1490, 10.1093/humrep/15.7.1490
Felberbaum, 1995, Preserved pituitary response under ovarian stimulation with hMG and GnRH-antagonists (cetrorelix) in women with tubal infertility, European Journal of Obstetrics, Gynecology and Reproductive Biology, 61, 151, 10.1016/0301-2115(95)02138-W
Franco, 2003, Jornal Brasileiro de Reproducao Assistida, 7, 26
Freitas GC, Cavagna M, Dzik A et al. 2004. Gonadotropin-releasing hormone (GnRH)-agonist versus GnRH-antagonist in ovarian stimulation for assisted reproductive techniques: results of a prospective randomized trial. In: Abstracts of the Scientific Oral and Poster Sessions of the 60th Annual Meeting if the ASRM, Philadelphia, PA, October 2004. Fertility and Sterility 82, P–271.
Friedler, 2003, Luteal phase characteristics following GnRH antagonist or agonist treatment: a randomized comparative study. In: Abstracts of the 19th Annual Meeting of the ESHRE, Madrid, Spain, June 2003, Human Reproduction, 18, O
Hughes, 1992, The routine use of gonadotropin-releasing hormone agonists prior to in vitro fertilization and gamete intrafallopian transfer: a meta-analysis of randomized trials, Fertility and Sterility, 58, 888, 10.1016/S0015-0282(16)55430-2
Inza R, Van Thillo G, Lombardi E et al. 2004. Reproductive performance in second IVF cycles treated with the use of either GnRH antagonists (-antag) vs GnRH agonists (-ag) after failure with long protocols with GnRH agonists: a prospective randomized trial. In: Abstracts of the Scientific Oral and Poster Sessions of the 60th Annual Meeting if the ASRM, Philadelphia, PA, October 2004. Fertility and Sterility 82, P–277.
Kim, 2004, Efficacy of a GnRH antagonist during early and late controlled ovarian hyperstimulation period in women with polycystic ovary syndrome undergoing IVF–ET. In: Abstracts of the 20th Annual Meeting of the ESHRE, Berlin, Germany, June 2004, Human Reproduction, 19, P
Kyono, 2005, A prospective randomized study of three different controlled ovarian hyperstimulation (COH) protocols. In: Abstracts of the Scientific Oral and Poster Sessions of the Conjoint Annual Meeting of the ASRM and the CFAS, Montreal, Canada, October 2005, Fertility and Sterility, 84, P
Lee, 2005, Ovarian response and follicular development for single-dose and multiple-dose protocols for gonadotropin-releasing hormone antagonist administration, Fertility and Sterility, 83, 1700, 10.1016/j.fertnstert.2004.12.037
Londra, 2003, GnRh antagonist versus GnRh agonist in good prognosis IVF patients. In: Abstracts of the 19th Annual Meeting of the ESHRE, Madrid, Spain, June 2003, Human Reproduction, 18, P
Loutradis, 2004, A modified gonadotropin-releasing hormone (GnRH) antagonist protocol failed to increase clinical pregnancy rates in comparison with the long GnRH protocol, Fertility and Sterility, 82, 1446, 10.1016/j.fertnstert.2004.04.051
Marci, 2005, GnRH antagonist in IVF poor-responder patients: results of a randomized trial, Reproductive BioMedicine Online, 11, 189, 10.1016/S1472-6483(10)60957-1
North American Ganirelix Study Group, 2001, Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation, Fertility and Sterility, 75, 38, 10.1016/S0015-0282(00)01638-1
Olivennes, 2000, Prospective randomized, controlled study of in vitro fertilization–embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (cetrorelix) or a depot formula of an LH-RH agonist (triptorelin), Fertility and Sterility, 73, 314, 10.1016/S0015-0282(99)00524-5
Olivennes, 1998, The use of GnRH antagonist (cetrorelix) in a single dose protocol in IVF–embryo transfer: a dose finding study of 3 versus 2 mg, Human Reproduction, 13, 2411, 10.1093/humrep/13.9.2411
Olivennes, 1994, The single or dual administration of the gonadotrophin-releasing hormone antagonist cetrorelix in an in-vitro fertilisation–embryo transfer program, Fertility and Sterility, 62, 468, 10.1016/S0015-0282(16)56933-7
Rombauts, 2006, A comparative randomized trial to assess the impact of oral contraceptive pretreatment on follicular growth and hormone profiles in GnRH antagonist-treated patients, Human Reproduction, 21, 95, 10.1093/humrep/dei302
Rongières-Bertrand, 1999, Revival of the natural cycles in in-vitro fertilization with the use of a new gonadotrophin-releasing hormone antagonist (cetrorelix): a pilot study with minimal stimulation, Human Reproduction, 14, 683, 10.1093/humrep/14.3.683
Xavier, 2005, A randomised study of GnRH antagonist (cetrorelix) versus agonist (busereline) for controlled ovarian stimulation: effect on safety and efficacy, European Journal of Obstetrics, Gynecology, and Reproductive Biology, 120, 185, 10.1016/j.ejogrb.2004.11.005